Nevertheless, our data are a proof-of-concept study, which suggest a potential role for PLK1 inhibition as a therapeutic target for ACC and provide a starting point for the development or identification of more efficacious compounds targeting PLK1. The gene discussed is PLK1; the disease is adrenal cortex carcinoma.